Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, as well as autoimmune, metabolic, ophthalmologic and other major diseases. Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. The company has also entered into strategic collaborations with Eli Lilly and Company, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners.